cas 701977-09-5, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)

Articles about 701977-09-5Total 10 be found

LIQUID PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF A SUBSTITUTED AMIDE
A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical compo
-
Page/Page column 12-13

(2009/05/28)

New efficient asymmetric synthesis of taranabant, a CB1R inverse agonist for the treatment of obesity
Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in th
Crump, Brian R.,Phenix, Brian D.,Spindler, Felix,Wallace, Debra J.,Campos, Kevin R.,Shultz, C. Scott,Klapars, Artis,Zewge, Daniel,McWilliams, J. Christopher,Krska, Shane,Sun, Yongkui,Chen, Cheng-Yi
experimental part
p. 84 - 90
(2010/04/22)

Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo
Chen, G-Yi,Frey, Lisa F.,Shultz, Scott,Wallace, Debra J.,Marcantonio, Karen,Payack, Joeseph F.,Vazquez, Enrique,Springfield, Shawn A.,Zhou, George,Liu, Ping,Kieczykowski, Gerard R.,Chen, Alex M.,Phenix, Brian D.,Singh, Utpal,Strine, Jeff,Izzo, Brianne,Krska, Shane W.
p. 616 - 623
(2012/12/31)

Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent
Being obese has various health problems that are related to type 2 diabetes mellitus, cardiovascular disease, hypertension, hyperlipidemia, and fibrinolytic abnormalities. Merck's taranabant (MK-0364), a CB1R inverse agonist, is currently in Phase 3 clini
Kim, Min-ah,Kim, Jong Yup,Song, Kwang-Seop,Kim, Jeongmin,Lee, Jinhwa
p. 12845 - 12852
(2008/03/27)

FORMATION OF TETRA-SUBSTITUTED ENAMIDES AND STEREOSELECTIVE REDUCTION THEREOF
The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compo
-
Page/Page column 18; 32

(2008/06/13)

COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY
The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.
-
(2008/06/13)

Cyanation of aromatic halides
A practical, ligand-free cyanation of aryl bromides employs Pd catalyst in combination with a non-toxic cyanide source, Mn[Fe(CN)6] (M=K or Na; n is 3 or 4), or a hydrate thereof, and a base. The reactions are performed in a polar aprotic solvents and provide the corresponding aryl nitrile in 83-96% yield, typically in less than 5 h.
-
Page/Page column 5; 11

(2008/06/13)

LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE
N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy} propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically accept
-
Page/Page column 19

(2008/06/13)

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.
Lin, Linus S.,Lanza Jr., Thomas J.,Jewell, James P.,Liu, Fing,Shah, Shrenik K.,Qi, Hongbo,Tong, Xinchun,Wang, Junying,Xu, Suoyu S.,Fong, Tung M.,Shen, Chun-Pyn,Lao, Julie,Xiao, Jing Chen,Shearman, Lauren P.,Stribling, D. Sloan,Rosko, Kimberly,Strack, Alison,Marsh, Donald J.,Feng, Yue,Kumar, Sanjeev,Samuel, Koppara,Yin, Wenji,Van Der Ploeg, Lex H. T.,Goulet, Mark T.,Hagmann, William K.
p. 7584 - 7587
(2007/10/03)

RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS
The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.
-
Page/Page column 42-43

(2010/02/10)